ATE230023T1 - Beeinflussung der zelladhäsion durch oligonukleotide - Google Patents
Beeinflussung der zelladhäsion durch oligonukleotideInfo
- Publication number
- ATE230023T1 ATE230023T1 AT91914455T AT91914455T ATE230023T1 AT E230023 T1 ATE230023 T1 AT E230023T1 AT 91914455 T AT91914455 T AT 91914455T AT 91914455 T AT91914455 T AT 91914455T AT E230023 T1 ATE230023 T1 AT E230023T1
- Authority
- AT
- Austria
- Prior art keywords
- cell adhesion
- oligonucleotide
- oligonucleotides
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3531—Hydrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56728690A | 1990-08-14 | 1990-08-14 | |
PCT/US1991/005209 WO1992003139A1 (en) | 1990-08-14 | 1991-07-23 | Oligonucleotide modulation of cell adhesion |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE230023T1 true ATE230023T1 (de) | 2003-01-15 |
Family
ID=24266532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT91914455T ATE230023T1 (de) | 1990-08-14 | 1991-07-23 | Beeinflussung der zelladhäsion durch oligonukleotide |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0544716B1 (de) |
JP (1) | JP2732544B2 (de) |
KR (1) | KR960009261B1 (de) |
AT (1) | ATE230023T1 (de) |
AU (1) | AU641539B2 (de) |
BR (2) | BR9106746A (de) |
CA (1) | CA2089563C (de) |
DE (1) | DE69133180T2 (de) |
DK (1) | DK0544716T3 (de) |
ES (1) | ES2188581T3 (de) |
FI (1) | FI930627A0 (de) |
HU (1) | HU217107B (de) |
NO (1) | NO930513L (de) |
WO (1) | WO1992003139A1 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827670A (en) * | 1990-08-02 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies |
US7449186B1 (en) * | 1990-08-02 | 2008-11-11 | Fred Hutchinson Cancer Research Center | Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies |
US5789573A (en) * | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
AU3598293A (en) * | 1992-01-31 | 1993-09-01 | Regents Of The University Of California, The | Method for making universal donor cells |
IL101600A (en) * | 1992-04-15 | 2000-02-29 | Yissum Res Dev Co | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
US5596090A (en) * | 1992-07-24 | 1997-01-21 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human VCAM-1 RNA |
AU673193B2 (en) * | 1992-09-02 | 1996-10-31 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US6399376B1 (en) * | 1993-11-05 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions |
DE4338704A1 (de) * | 1993-11-12 | 1995-05-18 | Hoechst Ag | Stabilisierte Oligonucleotide und deren Verwendung |
JPH08113591A (ja) * | 1994-10-14 | 1996-05-07 | Taiho Yakuhin Kogyo Kk | オリゴヌクレオチド及びこれを有効成分とする制癌剤 |
JPH10510433A (ja) * | 1995-06-06 | 1998-10-13 | アイシス・ファーマシューティカルス・インコーポレーテッド | 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド |
DE10019252A1 (de) * | 2000-04-18 | 2001-10-31 | Klaus Karl Degitz | Polydesoxyribonukleotide zur Hemmung der ICAM-1-Genexpression |
CN104531843A (zh) * | 2014-12-04 | 2015-04-22 | 杭州中翰金诺生物信息技术有限公司 | 肝癌诊断标志物黑素瘤细胞黏附分子及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006702A1 (en) * | 1988-01-21 | 1989-07-27 | Chemex Pharmaceuticals, Inc. | Selective inhibition of gene expression by photoactivatable oligonucleotides |
US5272263A (en) * | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
-
1991
- 1991-07-23 JP JP3513375A patent/JP2732544B2/ja not_active Expired - Lifetime
- 1991-07-23 DE DE69133180T patent/DE69133180T2/de not_active Expired - Lifetime
- 1991-07-23 AU AU83130/91A patent/AU641539B2/en not_active Expired
- 1991-07-23 ES ES91914455T patent/ES2188581T3/es not_active Expired - Lifetime
- 1991-07-23 AT AT91914455T patent/ATE230023T1/de not_active IP Right Cessation
- 1991-07-23 BR BR919106746A patent/BR9106746A/pt not_active Application Discontinuation
- 1991-07-23 WO PCT/US1991/005209 patent/WO1992003139A1/en active IP Right Grant
- 1991-07-23 EP EP91914455A patent/EP0544716B1/de not_active Expired - Lifetime
- 1991-07-23 CA CA002089563A patent/CA2089563C/en not_active Expired - Lifetime
- 1991-07-23 HU HU9300373A patent/HU217107B/hu not_active IP Right Cessation
- 1991-07-23 DK DK91914455T patent/DK0544716T3/da active
-
1993
- 1993-02-12 NO NO93930513A patent/NO930513L/no not_active Application Discontinuation
- 1993-02-12 FI FI930627A patent/FI930627A0/fi unknown
- 1993-02-15 KR KR93700438A patent/KR960009261B1/ko not_active IP Right Cessation
-
1997
- 1997-05-13 BR BR1100617-0A patent/BR1100617A/pt active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP0544716A1 (de) | 1993-06-09 |
DK0544716T3 (da) | 2003-03-17 |
DE69133180T2 (de) | 2003-07-24 |
KR960009261B1 (en) | 1996-07-16 |
HUT68322A (en) | 1995-06-28 |
EP0544716B1 (de) | 2002-12-18 |
FI930627A (fi) | 1993-02-12 |
BR1100617A (pt) | 2000-06-13 |
CA2089563A1 (en) | 1992-02-15 |
JP2732544B2 (ja) | 1998-03-30 |
CA2089563C (en) | 2004-04-06 |
AU8313091A (en) | 1992-03-17 |
NO930513L (no) | 1993-04-01 |
JPH05508998A (ja) | 1993-12-16 |
WO1992003139A1 (en) | 1992-03-05 |
HU217107B (hu) | 1999-11-29 |
DE69133180D1 (de) | 2003-01-30 |
EP0544716A4 (en) | 1994-09-14 |
FI930627A0 (fi) | 1993-02-12 |
NO930513D0 (no) | 1993-02-12 |
KR930701180A (ko) | 1993-06-11 |
AU641539B2 (en) | 1993-09-23 |
BR9106746A (pt) | 1993-07-20 |
HU9300373D0 (en) | 1993-05-28 |
ES2188581T3 (es) | 2003-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE231915T1 (de) | Beeinflussing der zelladhäsie durch oligonukleotide | |
EP0527818A4 (en) | Oligonucleotide modulation of arachidonic acid metabolism | |
ATE244506T1 (de) | Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein | |
ATE212063T1 (de) | Oligonukleotide modulation von protein kinase c | |
ATE230023T1 (de) | Beeinflussung der zelladhäsion durch oligonukleotide | |
Pizzuti et al. | Detection of β-nerve growth factor mRNA in the human fetal brain | |
NO924140L (no) | Oligonukleotidmodulering av arachidonsyre-metabolisme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0544716 Country of ref document: EP |
|
EELA | Cancelled due to lapse of time |